Long Shortz with Island Pharmaceuticals: Phase 2b trial into dengue fever kicks off
Stockhead’s Fraser Palamara sits down with Island Pharmaceuticals (ASX:ILA)  CEO and managing director David Foster to get the short end of the long story on the company’s latest news.
Future Market Insights1 天
Dengue Vaccines Industry Poised for Rapid Growth, Expected to Reach USD 1603.7 Million in ...
The dengue vaccine market is on track for robust growth, with increasing global awareness, governmental support, and ...
Island Pharmaceuticals starts phase 2b dengue trial
Progression to the phase 2b cohort follows recommendation of the Safety Review Committee (SRC) after it reviewed positive ...
HotCopper.com on MSN1 天
Island enrols first subjects for Phase 2b clinical trial for dengue fever drug
Island Pharmaceuticals Ltd (ASX:ILA) has successfully enrolled its first subjects for a Phase 2b clinical trial to test the ...
stockhead2 天
Health Check: Which stock just dumped 19% on earnings downgrade?
Dual-listed regenerative medicine company Avita Medical has seen its share price slide ~19% today on a downgrade of its ...